nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—Acute retention of urine—Furosemide—dilated cardiomyopathy	0.128	0.177	CcSEcCtD
Darifenacin—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.0142	0.0197	CcSEcCtD
Darifenacin—Bladder pain—Furosemide—dilated cardiomyopathy	0.0121	0.0168	CcSEcCtD
Darifenacin—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.0117	0.0162	CcSEcCtD
Darifenacin—Mental disability—Furosemide—dilated cardiomyopathy	0.0116	0.0161	CcSEcCtD
Darifenacin—Accidental injury—Lisinopril—dilated cardiomyopathy	0.0114	0.0157	CcSEcCtD
Darifenacin—Cough increased—Lisinopril—dilated cardiomyopathy	0.011	0.0152	CcSEcCtD
Darifenacin—Urinary retention—Furosemide—dilated cardiomyopathy	0.00925	0.0128	CcSEcCtD
Darifenacin—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00909	0.0126	CcSEcCtD
Darifenacin—Confusional state—Spironolactone—dilated cardiomyopathy	0.00886	0.0123	CcSEcCtD
Darifenacin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00879	0.0122	CcSEcCtD
Darifenacin—Injury—Lisinopril—dilated cardiomyopathy	0.00794	0.011	CcSEcCtD
Darifenacin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00781	0.0108	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00759	0.0105	CcSEcCtD
Darifenacin—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00745	0.0103	CcSEcCtD
Darifenacin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00724	0.01	CcSEcCtD
Darifenacin—Sweating—Furosemide—dilated cardiomyopathy	0.00719	0.00995	CcSEcCtD
Darifenacin—Face oedema—Lisinopril—dilated cardiomyopathy	0.00705	0.00976	CcSEcCtD
Darifenacin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00665	0.0092	CcSEcCtD
Darifenacin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.0066	0.00913	CcSEcCtD
Darifenacin—Breast disorder—Lisinopril—dilated cardiomyopathy	0.0066	0.00913	CcSEcCtD
Darifenacin—Visual impairment—Furosemide—dilated cardiomyopathy	0.00648	0.00898	CcSEcCtD
Darifenacin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00647	0.00897	CcSEcCtD
Darifenacin—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00636	0.00881	CcSEcCtD
Darifenacin—Influenza—Lisinopril—dilated cardiomyopathy	0.00631	0.00873	CcSEcCtD
Darifenacin—Eye disorder—Furosemide—dilated cardiomyopathy	0.00629	0.00871	CcSEcCtD
Darifenacin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00622	0.00861	CcSEcCtD
Darifenacin—Angiopathy—Furosemide—dilated cardiomyopathy	0.00611	0.00845	CcSEcCtD
Darifenacin—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00607	0.0084	CcSEcCtD
Darifenacin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00601	0.00833	CcSEcCtD
Darifenacin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00581	0.00805	CcSEcCtD
Darifenacin—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00581	0.00804	CcSEcCtD
Darifenacin—Flatulence—Furosemide—dilated cardiomyopathy	0.00577	0.00799	CcSEcCtD
Darifenacin—Weight increased—Lisinopril—dilated cardiomyopathy	0.00574	0.00795	CcSEcCtD
Darifenacin—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00574	0.00794	CcSEcCtD
Darifenacin—Vomiting—Spironolactone—dilated cardiomyopathy	0.00559	0.00774	CcSEcCtD
Darifenacin—Rash—Spironolactone—dilated cardiomyopathy	0.00554	0.00767	CcSEcCtD
Darifenacin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00554	0.00767	CcSEcCtD
Darifenacin—Vision blurred—Furosemide—dilated cardiomyopathy	0.00552	0.00764	CcSEcCtD
Darifenacin—Headache—Spironolactone—dilated cardiomyopathy	0.0055	0.00762	CcSEcCtD
Darifenacin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00547	0.00757	CcSEcCtD
Darifenacin—Sweating—Lisinopril—dilated cardiomyopathy	0.00539	0.00747	CcSEcCtD
Darifenacin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00528	0.00731	CcSEcCtD
Darifenacin—Nausea—Spironolactone—dilated cardiomyopathy	0.00522	0.00723	CcSEcCtD
Darifenacin—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00506	0.00701	CcSEcCtD
Darifenacin—Hallucination—Lisinopril—dilated cardiomyopathy	0.00502	0.00696	CcSEcCtD
Darifenacin—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00501	0.00694	CcSEcCtD
Darifenacin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00499	0.0069	CcSEcCtD
Darifenacin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00497	0.00689	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00495	0.00686	CcSEcCtD
Darifenacin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00495	0.00685	CcSEcCtD
Darifenacin—Dry mouth—Furosemide—dilated cardiomyopathy	0.00488	0.00675	CcSEcCtD
Darifenacin—Confusional state—Furosemide—dilated cardiomyopathy	0.00482	0.00668	CcSEcCtD
Darifenacin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00478	0.00662	CcSEcCtD
Darifenacin—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00477	0.00661	CcSEcCtD
Darifenacin—Shock—Furosemide—dilated cardiomyopathy	0.0047	0.00651	CcSEcCtD
Darifenacin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00469	0.00649	CcSEcCtD
Darifenacin—Skin disorder—Furosemide—dilated cardiomyopathy	0.00464	0.00643	CcSEcCtD
Darifenacin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00462	0.0064	CcSEcCtD
Darifenacin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00458	0.00634	CcSEcCtD
Darifenacin—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00455	0.0063	CcSEcCtD
Darifenacin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00442	0.00613	CcSEcCtD
Darifenacin—Flatulence—Lisinopril—dilated cardiomyopathy	0.00433	0.006	CcSEcCtD
Darifenacin—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.0043	0.00596	CcSEcCtD
Darifenacin—Back pain—Lisinopril—dilated cardiomyopathy	0.00425	0.00589	CcSEcCtD
Darifenacin—Somnolence—Furosemide—dilated cardiomyopathy	0.00425	0.00589	CcSEcCtD
Darifenacin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00414	0.00574	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00413	0.00572	CcSEcCtD
Darifenacin—Constipation—Furosemide—dilated cardiomyopathy	0.00409	0.00566	CcSEcCtD
Darifenacin—Pain—Furosemide—dilated cardiomyopathy	0.00409	0.00566	CcSEcCtD
Darifenacin—Angioedema—Lisinopril—dilated cardiomyopathy	0.00402	0.00556	CcSEcCtD
Darifenacin—Syncope—Lisinopril—dilated cardiomyopathy	0.00394	0.00546	CcSEcCtD
Darifenacin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00394	0.00546	CcSEcCtD
Darifenacin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00391	0.00541	CcSEcCtD
Darifenacin—Palpitations—Lisinopril—dilated cardiomyopathy	0.00388	0.00538	CcSEcCtD
Darifenacin—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00386	0.00535	CcSEcCtD
Darifenacin—Cough—Lisinopril—dilated cardiomyopathy	0.00384	0.00531	CcSEcCtD
Darifenacin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00378	0.00523	CcSEcCtD
Darifenacin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00374	0.00518	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00372	0.00515	CcSEcCtD
Darifenacin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00366	0.00507	CcSEcCtD
Darifenacin—Confusional state—Lisinopril—dilated cardiomyopathy	0.00362	0.00501	CcSEcCtD
Darifenacin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00359	0.00497	CcSEcCtD
Darifenacin—Oedema—Lisinopril—dilated cardiomyopathy	0.00359	0.00497	CcSEcCtD
Darifenacin—Infection—Lisinopril—dilated cardiomyopathy	0.00356	0.00493	CcSEcCtD
Darifenacin—Shock—Lisinopril—dilated cardiomyopathy	0.00353	0.00489	CcSEcCtD
Darifenacin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00352	0.00488	CcSEcCtD
Darifenacin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.0035	0.00485	CcSEcCtD
Darifenacin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00348	0.00482	CcSEcCtD
Darifenacin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00347	0.0048	CcSEcCtD
Darifenacin—Asthenia—Furosemide—dilated cardiomyopathy	0.00343	0.00475	CcSEcCtD
Darifenacin—Pruritus—Furosemide—dilated cardiomyopathy	0.00338	0.00468	CcSEcCtD
Darifenacin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00327	0.00453	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00327	0.00453	CcSEcCtD
Darifenacin—Insomnia—Lisinopril—dilated cardiomyopathy	0.00324	0.00449	CcSEcCtD
Darifenacin—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.0032	0.00443	CcSEcCtD
Darifenacin—Somnolence—Lisinopril—dilated cardiomyopathy	0.00319	0.00442	CcSEcCtD
Darifenacin—Dizziness—Furosemide—dilated cardiomyopathy	0.00316	0.00438	CcSEcCtD
Darifenacin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00316	0.00437	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.0031	0.00429	CcSEcCtD
Darifenacin—Constipation—Lisinopril—dilated cardiomyopathy	0.00307	0.00425	CcSEcCtD
Darifenacin—Pain—Lisinopril—dilated cardiomyopathy	0.00307	0.00425	CcSEcCtD
Darifenacin—Vomiting—Furosemide—dilated cardiomyopathy	0.00304	0.00421	CcSEcCtD
Darifenacin—Rash—Furosemide—dilated cardiomyopathy	0.00301	0.00417	CcSEcCtD
Darifenacin—Dermatitis—Furosemide—dilated cardiomyopathy	0.00301	0.00417	CcSEcCtD
Darifenacin—Headache—Furosemide—dilated cardiomyopathy	0.00299	0.00415	CcSEcCtD
Darifenacin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00296	0.00409	CcSEcCtD
Darifenacin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00293	0.00406	CcSEcCtD
Darifenacin—Nausea—Furosemide—dilated cardiomyopathy	0.00284	0.00393	CcSEcCtD
Darifenacin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00284	0.00393	CcSEcCtD
Darifenacin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00264	0.00366	CcSEcCtD
Darifenacin—Asthenia—Lisinopril—dilated cardiomyopathy	0.00257	0.00356	CcSEcCtD
Darifenacin—Pruritus—Lisinopril—dilated cardiomyopathy	0.00254	0.00351	CcSEcCtD
Darifenacin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00245	0.0034	CcSEcCtD
Darifenacin—Dizziness—Lisinopril—dilated cardiomyopathy	0.00237	0.00328	CcSEcCtD
Darifenacin—Vomiting—Lisinopril—dilated cardiomyopathy	0.00228	0.00316	CcSEcCtD
Darifenacin—Rash—Lisinopril—dilated cardiomyopathy	0.00226	0.00313	CcSEcCtD
Darifenacin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00226	0.00313	CcSEcCtD
Darifenacin—Headache—Lisinopril—dilated cardiomyopathy	0.00225	0.00311	CcSEcCtD
Darifenacin—Nausea—Lisinopril—dilated cardiomyopathy	0.00213	0.00295	CcSEcCtD
Darifenacin—CHRM4—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000681	0.00245	CbGpPWpGaD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.00068	0.00245	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000678	0.00244	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000674	0.00243	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000674	0.00243	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000672	0.00242	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000672	0.00242	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000666	0.0024	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000666	0.0024	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000657	0.00236	CbGpPWpGaD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000651	0.00234	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000627	0.00226	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000625	0.00225	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000619	0.00223	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000607	0.00219	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000605	0.00218	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000605	0.00218	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000603	0.00217	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000599	0.00216	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000598	0.00215	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000586	0.00211	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000574	0.00207	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000572	0.00206	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000567	0.00204	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000561	0.00202	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000556	0.002	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000555	0.002	CbGpPWpGaD
Darifenacin—CHRM1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000551	0.00198	CbGpPWpGaD
Darifenacin—CHRM3—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000549	0.00198	CbGpPWpGaD
Darifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000541	0.00195	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000532	0.00192	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000519	0.00187	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000518	0.00187	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000517	0.00186	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000514	0.00185	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000514	0.00185	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000512	0.00184	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000512	0.00184	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000512	0.00184	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000507	0.00182	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000507	0.00182	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ANKRD1—dilated cardiomyopathy	0.000496	0.00178	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000493	0.00177	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000492	0.00177	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000491	0.00177	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00049	0.00177	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000486	0.00175	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000486	0.00175	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000477	0.00172	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000476	0.00171	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000471	0.0017	CbGpPWpGaD
Darifenacin—CHRM4—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000466	0.00168	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—TAZ—dilated cardiomyopathy	0.000466	0.00168	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000462	0.00166	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000461	0.00166	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000459	0.00165	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000457	0.00165	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000456	0.00164	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000453	0.00163	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000453	0.00163	CbGpPWpGaD
Darifenacin—CHRM5—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000447	0.00161	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00043	0.00155	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00043	0.00155	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—SDHA—dilated cardiomyopathy	0.000422	0.00152	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000412	0.00148	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000412	0.00148	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000412	0.00148	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.0004	0.00144	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000395	0.00142	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000395	0.00142	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000394	0.00142	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000391	0.00141	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000391	0.00141	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00039	0.0014	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000388	0.00139	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000383	0.00138	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000375	0.00135	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000374	0.00135	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000374	0.00135	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000373	0.00134	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000371	0.00134	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00037	0.00133	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000365	0.00131	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000364	0.00131	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000363	0.00131	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00036	0.0013	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000352	0.00127	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000348	0.00125	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000342	0.00123	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000341	0.00123	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000337	0.00121	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000333	0.0012	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000331	0.00119	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000317	0.00114	CbGpPWpGaD
Darifenacin—CHRM1—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000315	0.00113	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000314	0.00113	CbGpPWpGaD
Darifenacin—CHRM3—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000314	0.00113	CbGpPWpGaD
Darifenacin—CHRM2—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.00031	0.00112	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000301	0.00108	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000301	0.00108	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000296	0.00107	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00029	0.00104	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00029	0.00104	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000289	0.00104	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000289	0.00104	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000288	0.00104	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000286	0.00103	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000286	0.00103	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000285	0.00103	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000285	0.00103	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000279	0.001	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000278	0.001	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000277	0.000997	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000274	0.000987	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000273	0.000983	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00027	0.000971	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000269	0.000968	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000266	0.000959	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000264	0.000949	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000264	0.000949	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000263	0.000946	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000263	0.000946	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000261	0.00094	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00026	0.000937	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00026	0.000936	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00026	0.000936	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00026	0.000936	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000258	0.000928	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000252	0.000907	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000249	0.000896	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000245	0.000882	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000244	0.000879	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000244	0.000877	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000242	0.00087	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000237	0.000854	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000237	0.000851	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000235	0.000844	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000234	0.000843	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000234	0.000841	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000233	0.00084	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000233	0.000838	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000231	0.000831	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000231	0.000831	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000223	0.000803	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000223	0.000803	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000222	0.000801	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000221	0.000797	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000221	0.000796	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000221	0.000796	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00022	0.000793	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000215	0.000773	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000212	0.000763	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000212	0.000762	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000212	0.000761	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000211	0.00076	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000209	0.000752	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000208	0.000748	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000206	0.00074	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000203	0.000729	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000203	0.000729	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000202	0.000727	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.0002	0.00072	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000199	0.000717	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000194	0.000698	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000192	0.000692	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000192	0.00069	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00019	0.000683	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000182	0.000656	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000178	0.000639	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000175	0.000631	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000175	0.000629	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000173	0.000623	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00017	0.000612	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000168	0.000606	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000165	0.000593	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000164	0.000592	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000164	0.00059	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000162	0.000584	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000161	0.000581	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000157	0.000565	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000157	0.000563	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000156	0.00056	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000156	0.00056	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000155	0.000559	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000155	0.000559	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000155	0.000558	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000154	0.000553	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000154	0.000553	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000149	0.000537	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000149	0.000535	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000147	0.00053	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000147	0.000528	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000145	0.000521	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000145	0.000521	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000144	0.000519	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000143	0.000514	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000143	0.000513	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000142	0.000512	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000141	0.000507	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000141	0.000506	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.00014	0.000505	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.00014	0.000503	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000139	0.000499	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000138	0.000498	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000131	0.000471	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000125	0.000451	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—AGT—dilated cardiomyopathy	0.000125	0.00045	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.00012	0.000431	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—AGT—dilated cardiomyopathy	0.00012	0.000431	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000119	0.00043	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000118	0.000425	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—GPX1—dilated cardiomyopathy	0.000115	0.000412	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000114	0.000409	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000113	0.000407	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000112	0.000404	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—CD36—dilated cardiomyopathy	0.000112	0.000401	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000101	0.000362	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AGT—dilated cardiomyopathy	0.0001	0.000361	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.9e-05	0.000356	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.87e-05	0.000355	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.77e-05	0.000352	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.76e-05	0.000351	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.73e-05	0.00035	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—EGFR—dilated cardiomyopathy	9.64e-05	0.000347	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.63e-05	0.000347	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	8.82e-05	0.000317	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RAC1—dilated cardiomyopathy	8.79e-05	0.000316	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RAC1—dilated cardiomyopathy	8.7e-05	0.000313	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—RAF1—dilated cardiomyopathy	8.67e-05	0.000312	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—AGT—dilated cardiomyopathy	8.42e-05	0.000303	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—AGT—dilated cardiomyopathy	8.4e-05	0.000302	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—AGT—dilated cardiomyopathy	8.32e-05	0.000299	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—RAF1—dilated cardiomyopathy	8.3e-05	0.000299	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	6.85e-05	0.000246	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.79e-05	0.000244	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.77e-05	0.000243	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.7e-05	0.000241	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	6.67e-05	0.00024	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	6.01e-05	0.000216	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—EGFR—dilated cardiomyopathy	5.95e-05	0.000214	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	5.85e-05	0.00021	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—RAF1—dilated cardiomyopathy	5.83e-05	0.00021	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—RAF1—dilated cardiomyopathy	5.77e-05	0.000208	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—EGFR—dilated cardiomyopathy	5.69e-05	0.000205	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	4.48e-05	0.000161	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4.36e-05	0.000157	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	4.01e-05	0.000144	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—EGFR—dilated cardiomyopathy	4e-05	0.000144	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—EGFR—dilated cardiomyopathy	3.96e-05	0.000142	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	3.93e-05	0.000141	CbGpPWpGaD
